Results 51 to 60 of about 20,950 (257)

Cutaneous Vasculitis During Secukinumab Treatment

European Journal of Case Reports in Internal Medicine, 2020
Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis.
Camila da Silva Cendon Duran, Mittermayer Barreto Santiago   +1 more
doaj   +1 more source

The parasitic worm product ES-62 up-regulates IL-22 production by γδ T cells in the murine model of Collagen-Induced Arthritis [PDF]

, 2014
S-62 is a phosphorylcholine (PC)-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae that acts to modulate the host immune response to promote the establishment of chronic helminth infection.
Harnett, Margaret, Harnett, William, Pineda, Miguel Angel   +2 more
core   +1 more source

T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis [PDF]

, 2020
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the progressive loss of axonal myelin in several areas of the central nervous system (CNS) that is responsible for clinical symptoms such as muscle spasms, optic neuritis ...
Amormino, Carola, Frascolla, Simone, Kunkl, Martina, Tuosto, Loretta, Volpe, Elisabetta   +4 more
core   +1 more source

Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database

Scientific Reports
Secukinumab is an anti-IL-17 monoclonal antibody approved for treating psoriasis and various arthritides. A comprehensive evaluation of its safety, especially in a real-world setting, is necessary.
Vishnu Eshwar, A. Kamath
semanticscholar   +1 more source

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

Frontiers in Medicine, 2023
Background Secukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials.
F. Sivera, V. Núñez-Monje, Cristina Campos-Fernández, Isabel Balaguer-Trull, M. Robustillo-Villarino, M. Aguilar-Zamora, Marta Garijo-Bufort, J. López-Gómez, Carolina Peña-González, I. De la morena, D. Bedoya-Sanchís, Liliya Yankova-Komsalova, Arantxa Conesa-Mateos, A. Martínez-Cristóbal, F. Navarro-Blasco, J. M. Senabre-Gallego, J. Alegre-Sancho   +16 more
semanticscholar   +1 more source

Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study

Dermatologic Therapy
The concept of a window of opportunity in hidradenitis suppurativa (HS) management suggests that early initiation of biological therapy leads to better outcomes, though its timing remains uncertain.
S. Haselgruber, Pablo Fernández-Crehuet-Serrano, M. D. Fernández-Ballesteros, A. Padial-Gómez, J. Hernández-Rodríguez, J. Ortiz-Álvarez, P. Navarro-Guillamón, Cristina Membrive-Jiménez, C. Cuenca-Barrales, A. Molina‐Leyva   +9 more
semanticscholar   +1 more source

Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2023
Biologics targeting IL‐23 and IL‐17 show efficacy and safety in the treatment of moderate‐to‐severe psoriasis.
L. Mastorino, P. Dapavo, S. Susca, C. Cariti, N. Siliquini, A. Verrone, E. Stroppiana, M. Ortoncelli, P. Quaglino, S. Ribero   +9 more
semanticscholar   +1 more source

Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges

Advanced Healthcare Materials, EarlyView.
This review explores the evolving role of microneedle systems in psoriasis management, highlighting their potential for enhanced drug delivery, diagnosis, and disease monitoring. It also discusses unmet clinical needs for psoriasis management and technical challenges, while outlining strategic directions to advance microneedle integration into routine ...
Fatma Moawad, Yasmine Ruel, Roxane Pouliot, Davide Brambilla   +3 more
wiley   +1 more source

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Therapeutic Advances in Chronic Disease, 2019
Background: Little is known about the treatment outcomes of secukinumab in clinical practice, which differ from those in clinical trials. The effectiveness of biologics may differ in psoriasis patients with previous biologics exposure.
Tzong-Yun Ger, Yu-Huei Huang, Rosaline Chung-yee Hui, Tsen-Fang Tsai, Hsien-Yi Chiu   +4 more
doaj   +1 more source

CRISPLD2 Attenuates Intervertebral Disc Degeneration by Suppressing Oxidative Stress‐Induced Ferroptosis through the miR‐548I‐IL17A Axis

Advanced Science, EarlyView.
This study identifies CRISPLD2 as a key protector against IVDD. By regulating ferroptosis through the CRISPLD2–miR‐548I–IL17A axis, CRISPLD2 maintains NPCs homeostasis and reduces oxidative stress. Restoring CRISPLD2 expression effectively alleviates disc degeneration and highlights a promising therapeutic strategy for discogenic low back pain ...
Yangyang Shi, Fudong Li, Tianyi Zhao, Kaiqiang Sun, Danying Zhang, Chen Yan, Ximing Xu, Jingchuang Sun, Xulin Hu, Xin Yong, Jiangang Shi, Yuan Wang   +11 more
wiley   +1 more source